News

Lupin’s Pithampur facility inspection concluded by US FDA without any observations

USFDA_observations

Pharma major Lupin Limited (Lupin) announced today the successful completion of a GMP inspection as well as a PAI inspection (Prior Approval Inspection) carried out by the US FDA at its Pithampur manufacturing facility – Unit 1 without any observations. The inspection which started on Monday, July 24th concluded today afternoon.

USFDA_observations

Don't be shellfish...Share on Facebook0Share on Google+0Share on LinkedIn0Share on StumbleUpon0Pin on Pinterest0Tweet about this on Twitter0
Click to comment

Leave a Reply

Your email address will not be published. Required fields are marked *

You may use these HTML tags and attributes: <a href="" title=""> <abbr title=""> <acronym title=""> <b> <blockquote cite=""> <cite> <code> <del datetime=""> <em> <i> <q cite=""> <strike> <strong>

Most Popular

To Top